A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorRuijin Hospital
About this trial
This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.
Eligibility criteria
Qualifiers
Age 18-75 years, female gender;
Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;
The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;
At least an interval of 1 month since the last local treatment;
Disqualifiers
Liver function Child-Pugh class C;
Systemic widespread metastasis, with an expected survival of < 3 months;
History of esophageal (gastric fundus) variceal bleeding within the past month;
Dysfunction or failure of vital organs;
Trial design
Treatments tested in this trial
- Multi-mode tumor treatment system
- Radiofrequency ablation therapeutic apparatus
Treatment groups
10 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov